GB Sciences (OTCMKTS:GBLX – Get Rating) is one of 440 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare GB Sciences to similar businesses based on the strength of its dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.
Insider & Institutional Ownership
13.6% of GB Sciences shares are held by institutional investors. Comparatively, 29.5% of shares of all “Biotechnology” companies are held by institutional investors. 23.3% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares GB Sciences and its peers gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| GB Sciences | N/A | N/A | -0.04 |
| GB Sciences Competitors | $337.70 million | $40.71 million | -3.63 |
Profitability
This table compares GB Sciences and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GB Sciences | N/A | N/A | N/A |
| GB Sciences Competitors | -1,071.94% | -86.67% | -28.49% |
Analyst Ratings
This is a summary of recent recommendations for GB Sciences and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GB Sciences | 0 | 0 | 0 | 0 | N/A |
| GB Sciences Competitors | 916 | 2400 | 7408 | 86 | 2.62 |
As a group, “Biotechnology” companies have a potential upside of 131.15%. Given GB Sciences’ peers higher probable upside, analysts plainly believe GB Sciences has less favorable growth aspects than its peers.
GB Sciences Company Profile
GB Sciences, Inc. is a phytomedical research and biopharmaceutical drug development company, which engages in the research and development of plant-based medicines and plans to produce plant-inspired and complex therapeutic mixtures based on its portfolio of intellectual property. The company was founded on April 4, 2001 and is headquartered in Las Vegas, NV.
Receive News & Ratings for GB Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GB Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
